Navigation Links
It's Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
Date:9/11/2007

PARAMUS, N.J., Sept. 11 /PRNewswire-USNewswire/ -- If you have or have ever had chronic heartburn, you may be at risk for Barrett's esophagus, a serious complication of chronic, severe gastroesophageal reflux disease (GERD). Barrett's esophagus has been recognized as a major risk factor for developing cancer of the esophagus, the seventh deadliest cancer in men in the United States.

Barrett's esophagus is marked by cellular changes in the lining of the esophagus, which can progress to low-grade, and then high-grade dysplasia -- a level that is highly pre-malignant. These abnormal cellular changes can lead to a type of cancer called esophageal adenocarcinoma, the fastest rising malignancy in the United States, according to the National Institutes of Health.

The Valley Hospital's Center for Barrett's Esophagus and GERD provides cutting-edge diagnostic, treatment, management, and research services for these related conditions. The Center is one of the most comprehensive on the East Coast and unique to northern New Jersey. The physician team includes board-certified gastroenterologists and thoracic surgeons.

Diagnostic and treatment methods available at the Center include endoscopy, medications to reduce acid, minimally invasive surgical procedures to repair hiatal hernias and to prevent acid reflux, radiofrequency ablation to destroy abnormal cells, endoscopic mucosal resection to remove nodules within Barrett's esophagus, and esophageal cancer surgery.

Robert J. Korst, M.D., Medical Director of The Valley Hospital's Daniel and Gloria Blumenthal Cancer Center, and Director of Thoracic Surgery, says he and physicians at the Center for Barrett's Esophagus and GERD must take a two-prong approach to treating Barrett's esophagus that both destroys the abnormal lining and stops acid reflux.

"Radiofrequency ablation can get rid of the lining, but if the GERD is not controlled, those abnormal cells can grow back and put the patient at risk for cancer once again," he adds.

If Barrett's esophagus progresses into high-grade dysplasia or cancer, the entire esophagus must be removed. Dr. Korst specializes in the treatment and research of esophageal cancer and is highly experienced in using both laparoscopic and traditional surgical methods to remove the esophagus and construct a new one by stretching the stomach.

Barrett's esophagus is most prevalent in middle-aged and elderly Caucasian men but can affect anyone, even those who do not have obvious symptoms of gastroesophageal reflux disease. To learn more about Barrett's esophagus or to schedule an appointment for an evaluation, call The Valley Hospital Center for Barrett's Esophagus and GERD at 201-634-5789


'/>"/>
SOURCE The Valley Hospital
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
5. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
8. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
9. Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
10. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
11. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... -- While nearly three-quarters of Americans (71%) are aware of ... only about half report taking any steps to prevent ... new survey announced today by Hologic (Nasdaq: ... Month, Hologic is raising awareness of this major threat ... Osteoporosis is a disease that causes low ...
(Date:5/2/2016)... The global  ultrasound device ... by 2024, according to a new report published ... the sonography market include expanding applications of the ... periodic ultrasound screenings of the breast for breast ... ) High Intensity Focused Ultrasound (HIFU) ...
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... In April, Amerec launched a new website designed ... find the best steam and sauna solutions. , First, the Amerec website has been ... brings all of the site’s features, especially the Steam Builder Tool , to ...
(Date:5/3/2016)... ... , ... For over 23 years, Doctors on Liens has committed ... doctors and therapists treating personal injury patients on a lien basis. With the recent ... Rehabilitation in Santa Monica, Doctors on Liens is continuing that tradition. While the ...
(Date:5/3/2016)... ... ... Registration is now open for the 31st annual AIDS Walk Boston & 5K Run ... the Esplanade. The event regularly draws thousands of participants, making it AIDS Action Committee’s largest ... sanctioned by the USA Track & Field Association. , The AIDS Walk & 5K ...
(Date:5/3/2016)... Monica, California (PRWEB) , ... May 03, 2016 , ... ... surgery practice in late 2014, incorporating the injectable filler into his menu of ... of aesthetic transformation. Now, more than a year later, he’s still improving his approach ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... university, has announced today the launch of its Associates and Bachelor's degrees in ... Emeritus of The Rockefeller University, Dr. Torsten N. Wiesel; Chairman and CEO of ...
Breaking Medicine News(10 mins):